412 related articles for article (PubMed ID: 27229140)
21. Histone Lysine-to-Methionine Mutation as Anticancer Drug Target.
Yang J; Qiu Q; Chen L
Adv Exp Med Biol; 2021; 1283():85-96. PubMed ID: 33155140
[TBL] [Abstract][Full Text] [Related]
22. Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo.
Yokoyama Y; Hieda M; Nishioka Y; Matsumoto A; Higashi S; Kimura H; Yamamoto H; Mori M; Matsuura S; Matsuura N
Cancer Sci; 2013 Jul; 104(7):889-95. PubMed ID: 23557258
[TBL] [Abstract][Full Text] [Related]
23. Molecular basis for the role of oncogenic histone mutations in modulating H3K36 methylation.
Zhang Y; Shan CM; Wang J; Bao K; Tong L; Jia S
Sci Rep; 2017 Mar; 7():43906. PubMed ID: 28256625
[TBL] [Abstract][Full Text] [Related]
24. Cryo-EM structure of SETD2/Set2 methyltransferase bound to a nucleosome containing oncohistone mutations.
Liu Y; Zhang Y; Xue H; Cao M; Bai G; Mu Z; Yao Y; Sun S; Fang D; Huang J
Cell Discov; 2021 May; 7(1):32. PubMed ID: 33972509
[TBL] [Abstract][Full Text] [Related]
25. Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression.
Jain SU; Khazaei S; Marchione DM; Lundgren SM; Wang X; Weinberg DN; Deshmukh S; Juretic N; Lu C; Allis CD; Garcia BA; Jabado N; Lewis PW
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27354-27364. PubMed ID: 33067396
[TBL] [Abstract][Full Text] [Related]
26. The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma.
Amary MF; Berisha F; Mozela R; Gibbons R; Guttridge A; O'Donnell P; Baumhoer D; Tirabosco R; Flanagan AM
Histopathology; 2016 Jul; 69(1):121-7. PubMed ID: 26844533
[TBL] [Abstract][Full Text] [Related]
27. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
Morishita M; Mevius D; di Luccio E
BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
[TBL] [Abstract][Full Text] [Related]
28. SETD2-dependent H3K36me3 plays a critical role in epigenetic regulation of the HPV31 life cycle.
Gautam D; Johnson BA; Mac M; Moody CA
PLoS Pathog; 2018 Oct; 14(10):e1007367. PubMed ID: 30312361
[TBL] [Abstract][Full Text] [Related]
29. Anti-histone H3.3K36M Antibody is a Highly Sensitive and Specific Immunohistochemistry Marker for the Diagnosis of Chondroblastoma. A Validation Based on Study 136 Cases Comprising Chondroblastoma and its Mimics from Single a Centre in India.
Hui M; Uppin SG; Narayanan R; Kancherla NR; Kamble A; B RR; Patnala C
Int J Surg Pathol; 2023 Jun; 31(4):375-386. PubMed ID: 35786027
[No Abstract] [Full Text] [Related]
30. H3.3 K36M Mutation as a Clinical Diagnosis Method of Suspected Chondroblastoma Cases.
Mu H; Jiang Y; Xue L; Hua Y; Lin J; Cai Z
Orthop Surg; 2021 Apr; 13(2):616-622. PubMed ID: 33620145
[TBL] [Abstract][Full Text] [Related]
31. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.
Pfister SX; Ahrabi S; Zalmas LP; Sarkar S; Aymard F; Bachrati CZ; Helleday T; Legube G; La Thangue NB; Porter AC; Humphrey TC
Cell Rep; 2014 Jun; 7(6):2006-18. PubMed ID: 24931610
[TBL] [Abstract][Full Text] [Related]
32. The H3.3 G34W oncohistone mutation increases K36 methylation by the protein lysine methyltransferase NSD1.
Bröhm A; Schoch T; Grünberger D; Khella MS; Schuhmacher MK; Weirich S; Jeltsch A
Biochimie; 2022 Jul; 198():86-91. PubMed ID: 35341929
[TBL] [Abstract][Full Text] [Related]
33. SET DOMAIN GROUP 708, a histone H3 lysine 36-specific methyltransferase, controls flowering time in rice (Oryza sativa).
Liu B; Wei G; Shi J; Jin J; Shen T; Ni T; Shen WH; Yu Y; Dong A
New Phytol; 2016 Apr; 210(2):577-88. PubMed ID: 26639303
[TBL] [Abstract][Full Text] [Related]
34.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
35. Histone H3K36M mutation and trimethylation patterns in chondroblastoma.
Lu C; Ramirez D; Hwang S; Jungbluth A; Frosina D; Ntiamoah P; Healey J; Zhu G; Chen W; Klein M; Hameed M
Histopathology; 2019 Jan; 74(2):291-299. PubMed ID: 30098026
[TBL] [Abstract][Full Text] [Related]
36. S-adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3.
Jayaram H; Hoelper D; Jain SU; Cantone N; Lundgren SM; Poy F; Allis CD; Cummings R; Bellon S; Lewis PW
Proc Natl Acad Sci U S A; 2016 May; 113(22):6182-7. PubMed ID: 27185940
[TBL] [Abstract][Full Text] [Related]
37. H3F3 mutation status of giant cell tumors of the bone, chondroblastomas and their mimics: a combined high resolution melting and pyrosequencing approach.
Kervarrec T; Collin C; Larousserie F; Bouvier C; Aubert S; Gomez-Brouchet A; Marie B; Miquelestorena-Standley E; Le Nail LR; Avril P; Christophe Pagès J; de Pinieux G
Mod Pathol; 2017 Mar; 30(3):393-406. PubMed ID: 28059095
[TBL] [Abstract][Full Text] [Related]
38. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
[TBL] [Abstract][Full Text] [Related]
39. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains.
Rice JC; Briggs SD; Ueberheide B; Barber CM; Shabanowitz J; Hunt DF; Shinkai Y; Allis CD
Mol Cell; 2003 Dec; 12(6):1591-8. PubMed ID: 14690610
[TBL] [Abstract][Full Text] [Related]
40. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Martinelli G; Mancini M; De Benedittis C; Rondoni M; Papayannidis C; Manfrini M; Meggendorfer M; Calogero R; Guadagnuolo V; Fontana MC; Bavaro L; Padella A; Zago E; Pagano L; Zanotti R; Scaffidi L; Specchia G; Albano F; Merante S; Elena C; Savini P; Gangemi D; Tosi P; Ciceri F; Poletti G; Riccioni L; Morigi F; Delledonne M; Haferlach T; Cavo M; Valent P; Soverini S
Leukemia; 2018 Jan; 32(1):139-148. PubMed ID: 28663576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
